Which has higher earnings & valuation, PEN or ZBH?

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 9.04 $177.69M $4.07 79.18 Zimmer Biomet $8.23B 2.27 $705.20M $4.11 23.83

Is PEN or ZBH more profitable?

Penumbra has a net margin of 10.67% compared to Zimmer Biomet's net margin of 9.48%. Zimmer Biomet's return on equity of 13.12% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% Zimmer Biomet 9.48% 13.12% 7.23%

Does the media refer more to PEN or ZBH?

In the previous week, Zimmer Biomet had 3 more articles in the media than Penumbra. MarketBeat recorded 11 mentions for Zimmer Biomet and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.58 beat Zimmer Biomet's score of 1.35 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zimmer Biomet 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BSX or ZBH?

In the previous week, Boston Scientific had 29 more articles in the media than Zimmer Biomet. MarketBeat recorded 40 mentions for Boston Scientific and 11 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.35 beat Boston Scientific's score of 0.96 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 25 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Zimmer Biomet 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ZBH or BDX?

In the previous week, Becton, Dickinson and Company had 10 more articles in the media than Zimmer Biomet. MarketBeat recorded 21 mentions for Becton, Dickinson and Company and 11 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.35 beat Becton, Dickinson and Company's score of 1.35 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 15 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZBH or EW?

In the previous week, Edwards Lifesciences had 10 more articles in the media than Zimmer Biomet. MarketBeat recorded 21 mentions for Edwards Lifesciences and 11 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.35 beat Edwards Lifesciences' score of 1.08 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edwards Lifesciences 13 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZBH or IDXX?

In the previous week, Zimmer Biomet had 1 more articles in the media than IDEXX Laboratories. MarketBeat recorded 11 mentions for Zimmer Biomet and 10 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.38 beat Zimmer Biomet's score of 1.35 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zimmer Biomet (ZBH) Competitors

$97.94 -0.98 (-0.99%)

As of 09/4/2026 03:58 PM Eastern

Compare

ZBH vs. PEN, BSX, BDX, EW, and IDXX

Should you buy Zimmer Biomet stock or one of its competitors? Zimmer Biomet's main competitors and comparable companies include Penumbra (PEN), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), and IDEXX Laboratories (IDXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Zimmer Biomet compare to Penumbra?

Penumbra (NYSE:PEN) and Zimmer Biomet (NYSE:ZBH) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Penumbra has a net margin of 10.67% compared to Zimmer Biomet's net margin of 9.48%. Zimmer Biomet's return on equity of 13.12% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
Zimmer Biomet	9.48%	13.12%	7.23%

In the previous week, Zimmer Biomet had 3 more articles in the media than Penumbra. MarketBeat recorded 11 mentions for Zimmer Biomet and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.58 beat Zimmer Biomet's score of 1.35 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zimmer Biomet	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Penumbra currently has a consensus target price of $367.07, indicating a potential upside of 13.90%. Zimmer Biomet has a consensus target price of $104.42, indicating a potential upside of 6.62%. Given Penumbra's higher possible upside, equities research analysts plainly believe Penumbra is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.26

88.9% of Penumbra shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.04	$177.69M	$4.07	79.18
Zimmer Biomet	$8.23B	2.27	$705.20M	$4.11	23.83

Summary

Zimmer Biomet beats Penumbra on 9 of the 17 factors compared between the two stocks.

How does Zimmer Biomet compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and Zimmer Biomet (NYSE:ZBH) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Boston Scientific has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Boston Scientific has higher revenue and earnings than Zimmer Biomet. Boston Scientific is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07B	3.45	$2.90B	$2.47	19.37
Zimmer Biomet	$8.23B	2.27	$705.20M	$4.11	23.83

Boston Scientific presently has a consensus target price of $71.62, suggesting a potential upside of 49.67%. Zimmer Biomet has a consensus target price of $104.42, suggesting a potential upside of 6.62%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities research analysts clearly believe Boston Scientific is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	2 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.71
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.26

Boston Scientific has a net margin of 17.50% compared to Zimmer Biomet's net margin of 9.48%. Boston Scientific's return on equity of 19.28% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.50%	19.28%	10.89%
Zimmer Biomet	9.48%	13.12%	7.23%

In the previous week, Boston Scientific had 29 more articles in the media than Zimmer Biomet. MarketBeat recorded 40 mentions for Boston Scientific and 11 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.35 beat Boston Scientific's score of 0.96 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	25 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Zimmer Biomet	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Boston Scientific beats Zimmer Biomet on 12 of the 17 factors compared between the two stocks.

How does Zimmer Biomet compare to Becton, Dickinson and Company?

Zimmer Biomet (NYSE:ZBH) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.0%. Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.3%. Zimmer Biomet pays out 23.4% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 126.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Becton, Dickinson and Company has increased its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zimmer Biomet has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Becton, Dickinson and Company has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Becton, Dickinson and Company had 10 more articles in the media than Zimmer Biomet. MarketBeat recorded 21 mentions for Becton, Dickinson and Company and 11 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.35 beat Becton, Dickinson and Company's score of 1.35 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Becton, Dickinson and Company	15 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has a net margin of 9.48% compared to Becton, Dickinson and Company's net margin of 4.52%. Becton, Dickinson and Company's return on equity of 14.79% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.48%	13.12%	7.23%
Becton, Dickinson and Company	4.52%	14.79%	6.93%

Becton, Dickinson and Company has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.27	$705.20M	$4.11	23.83
Becton, Dickinson and Company	$21.84B	2.33	$1.68B	$3.32	55.66

Zimmer Biomet currently has a consensus target price of $104.42, indicating a potential upside of 6.62%. Becton, Dickinson and Company has a consensus target price of $187.67, indicating a potential upside of 1.56%. Given Zimmer Biomet's higher probable upside, equities analysts clearly believe Zimmer Biomet is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.26
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

Summary

Zimmer Biomet and Becton, Dickinson and Company tied by winning 10 of the 20 factors compared between the two stocks.

How does Zimmer Biomet compare to Edwards Lifesciences?

Zimmer Biomet (NYSE:ZBH) and Edwards Lifesciences (NYSE:EW) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Zimmer Biomet presently has a consensus target price of $104.42, suggesting a potential upside of 6.62%. Edwards Lifesciences has a consensus target price of $100.27, suggesting a potential upside of 11.41%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.26
Edwards Lifesciences	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.74

88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Edwards Lifesciences has lower revenue, but higher earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.27	$705.20M	$4.11	23.83
Edwards Lifesciences	$6.07B	8.54	$1.07B	$1.74	51.72

Zimmer Biomet has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

In the previous week, Edwards Lifesciences had 10 more articles in the media than Zimmer Biomet. MarketBeat recorded 21 mentions for Edwards Lifesciences and 11 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.35 beat Edwards Lifesciences' score of 1.08 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edwards Lifesciences	13 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edwards Lifesciences has a net margin of 15.43% compared to Zimmer Biomet's net margin of 9.48%. Edwards Lifesciences' return on equity of 15.68% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.48%	13.12%	7.23%
Edwards Lifesciences	15.43%	15.68%	12.05%

Summary

Edwards Lifesciences beats Zimmer Biomet on 11 of the 17 factors compared between the two stocks.

How does Zimmer Biomet compare to IDEXX Laboratories?

Zimmer Biomet (NYSE:ZBH) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IDEXX Laboratories has lower revenue, but higher earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.27	$705.20M	$4.11	23.83
IDEXX Laboratories	$4.30B	9.80	$1.06B	$14.22	37.65

In the previous week, Zimmer Biomet had 1 more articles in the media than IDEXX Laboratories. MarketBeat recorded 11 mentions for Zimmer Biomet and 10 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.38 beat Zimmer Biomet's score of 1.35 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

IDEXX Laboratories has a net margin of 25.03% compared to Zimmer Biomet's net margin of 9.48%. IDEXX Laboratories' return on equity of 71.96% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.48%	13.12%	7.23%
IDEXX Laboratories	25.03%	71.96%	33.60%

Zimmer Biomet presently has a consensus target price of $104.42, indicating a potential upside of 6.62%. IDEXX Laboratories has a consensus target price of $747.00, indicating a potential upside of 39.53%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe IDEXX Laboratories is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.26
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

IDEXX Laboratories beats Zimmer Biomet on 11 of the 16 factors compared between the two stocks.

Get Zimmer Biomet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBH vs. The Competition

Export

Metric	Zimmer Biomet	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$18.71B	$5.76B	$7.25B	$23.65B
Dividend Yield	0.98%	1.76%	2.53%	3.73%
P/E Ratio	23.83	21.48	213.35	25.43
Price / Sales	2.27	72.94	625.09	20.84
Price / Cash	7.14	32.98	77.08	33.54
Price / Book	1.48	6.06	12.85	7.61
Net Income	$705.20M	$150.92M	$3.49B	$1.07B
7 Day Performance	-3.13%	-1.22%	1.04%	-0.05%
1 Month Performance	-0.15%	1.96%	5.52%	-0.24%
1 Year Performance	-7.24%	10.79%	24.39%	12.80%

Zimmer Biomet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBH Zimmer Biomet	3.9171 of 5 stars	$97.94 -1.0%	$104.42 +6.6%	-6.5%	$18.71B	$8.23B	23.83	17,000	Positive News Dividend Announcement
PEN Penumbra	3.6366 of 5 stars	$323.36 +0.5%	$367.07 +13.5%	+15.3%	$12.67B	$1.40B	79.45	4,700	Positive News
BSX Boston Scientific	4.8007 of 5 stars	$48.35 +3.2%	$71.62 +48.1%	-55.4%	$67.88B	$20.07B	19.57	59,000	Trending News Options Volume
BDX Becton, Dickinson and Company	4.1487 of 5 stars	$188.13 -0.7%	$187.67 -0.2%	-3.4%	$52.22B	$21.84B	56.67	72,000	Positive News
EW Edwards Lifesciences	3.4317 of 5 stars	$90.86 +0.7%	$100.27 +10.4%	+11.1%	$51.94B	$6.07B	52.22	16,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZBH) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, BSX, BDX, EW, and IDXX

How does Zimmer Biomet compare to Penumbra?

Summary

How does Zimmer Biomet compare to Boston Scientific?

Summary

How does Zimmer Biomet compare to Becton, Dickinson and Company?

Summary

How does Zimmer Biomet compare to Edwards Lifesciences?

Summary

How does Zimmer Biomet compare to IDEXX Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, BSX, BDX, EW, and IDXX

How does Zimmer Biomet compare to Penumbra?

Is PEN or ZBH more profitable?

Does the media refer more to PEN or ZBH?

Which has more volatility and risk, PEN or ZBH?

Do analysts prefer PEN or ZBH?

Do insiders and institutionals believe in PEN or ZBH?

Which has higher earnings & valuation, PEN or ZBH?

Summary

How does Zimmer Biomet compare to Boston Scientific?

Which has more risk & volatility, BSX or ZBH?

Do institutionals and insiders hold more shares of BSX or ZBH?

Which has preferable earnings & valuation, BSX or ZBH?

Do analysts recommend BSX or ZBH?

Is BSX or ZBH more profitable?

Does the media refer more to BSX or ZBH?

Summary

How does Zimmer Biomet compare to Becton, Dickinson and Company?

Is ZBH or BDX a better dividend stock?

Which has more risk and volatility, ZBH or BDX?

Do institutionals and insiders believe in ZBH or BDX?

Does the media prefer ZBH or BDX?

Is ZBH or BDX more profitable?

Which has better earnings and valuation, ZBH or BDX?

Do analysts rate ZBH or BDX?

Summary

How does Zimmer Biomet compare to Edwards Lifesciences?

Do analysts rate ZBH or EW?

Do insiders and institutionals have more ownership in ZBH or EW?

Which has higher valuation and earnings, ZBH or EW?

Which has more risk and volatility, ZBH or EW?

Does the media favor ZBH or EW?

Is ZBH or EW more profitable?

Summary

How does Zimmer Biomet compare to IDEXX Laboratories?

Do insiders & institutionals believe in ZBH or IDXX?

Which has preferable earnings & valuation, ZBH or IDXX?

Does the media favor ZBH or IDXX?

Which has more risk and volatility, ZBH or IDXX?

Is ZBH or IDXX more profitable?

Do analysts prefer ZBH or IDXX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools